Files
republic-os/legal/us/code/title-42/chapter-6a/section-285a-10.md
T
Fabio 76b8ec33a7 Legal corpus: the complete U.S. Code (59,740 sections, all 53 titles)
Ingested titles 12–51 and 54 from OLRC USLM XML @119-100 (the whole Code
now, uniform edition; Title 53 is reserved/empty). LegalText 11,221 ->
59,740; repo total 105,704 records. Deterministic (byte-identical rerun,
verified on Title 42's 8,356 sections); make check green. make
legal-us-code default now covers every title.

Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
2026-07-06 10:51:44 -04:00

5.1 KiB
Raw Blame History

type, title, description, jurisdiction, corpus, kind, title_number, title_name, chapter_number, chapter_name, section, citation, status, release_point, release_date, source, source_url, source_identifier, source_file, source_hash, raw_snapshot_hash, text_hash, retrieved_at, confidence, tags
type title description jurisdiction corpus kind title_number title_name chapter_number chapter_name section citation status release_point release_date source source_url source_identifier source_file source_hash raw_snapshot_hash text_hash retrieved_at confidence tags
LegalText 42 U.S.C. § 285a10 Research, information, and education with respect to blood cancer us united_states_code code_section 42 THE PUBLIC HEALTH AND WELFARE 6A PUBLIC HEALTH SERVICE 285a10 42 U.S.C. § 285a10 current 119-100 2026-06-26 official https://uscode.house.gov/download/releasepoints/us/pl/119/100/xml_usc42@119-100.zip /us/usc/t42/s285a10 data/legal/raw/us/code/title-42/usc42.xml 79f7790aecc0cf05eb3443845c1097a7c40feb0e814801c78e1b861f2be23db9 644321055a08eb1f260a6a3e31ac157fa024756abf612a9fd6857e7e400cf24e 414c7083281ac74e9a5f27fda9c5a6368d95ab7d6d866cacbcce4cbd2921605e 2026-07-04 official
legal
us-code

42 U.S.C. § 285a10 - Research, information, and education with respect to blood cancer

Text

(a) Joe Moakley Research Excellence Program (1) In general The Director of NIH shall expand, intensify, and coordinate programs for the conduct and support of research with respect to blood cancer, and particularly with respect to leukemia, lymphoma, and multiple myeloma.

(2) Administration The Director of NIH shall carry out this subsection through the Director of the National Cancer Institute and in collaboration with any other agencies that the Director determines to be appropriate.

(b) Geraldine Ferraro Cancer Education Program (1) In general The Secretary shall direct the appropriate agency within the Department of Health and Human Services, in collaboration with the Director of NIH, to establish and carry out a program to provide information and education for patients and the general public with respect to blood cancer, and particularly with respect to the treatment of leukemia, lymphoma, and multiple myeloma.

(2) Administration The Agency determined by the Secretary under paragraph (1) shall carry out this subsection in collaboration with private health organizations that have national education and patient assistance programs on blood-related cancers.

(July 1, 1944, ch. 373, title IV, § 417D, as added Pub. L. 107172, § 3, May 14, 2002, 116 Stat. 541; amended Pub. L. 109482, title I, § 103(b)(17), Jan. 15, 2007, 120 Stat. 3688; Pub. L. 115180, title II, § 204(a), June 5, 2018, 132 Stat. 1390.)

Notes

Editorial Notes

Amendments2018—Pub. L. 115180 made technical correction to directory language of Pub. L. 107172, § 3, which enacted this section. 2007—Subsec. (a)(3). Pub. L. 109482, § 103(b)(17)(A), struck out heading and text of par. (3). Text read as follows: “For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.” Subsec. (b)(3). Pub. L. 109482, § 103(b)(17)(B), struck out heading and text of par. (3). Text read as follows: “For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.”

Statutory Notes and Related Subsidiaries

Effective Date of 2018 AmendmentPub. L. 115180, title II, § 204(b), June 5, 2018, 132 Stat. 1390, provided that: “The amendment made by subsection (a) [amending section 3 of Pub. L. 107172] shall take effect as if included in section 3 of the Hematological Cancer Research Investment and Education Act of 2002 (Public Law 107172; 116 Stat. 541) [enacting this section].”

Effective Date of 2007 AmendmentAmendment by Pub. L. 109482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109482, set out as a note under section 281 of this title.

Congressional FindingsPub. L. 107172, § 2, May 14, 2002, 116 Stat. 541, provided that: “Congress finds that: “(1) An estimated 109,500 people in the United States will be diagnosed with leukemia, lymphoma, and multiple myeloma in 2001. “(2) New cases of the blood cancers described in paragraph (1) account for 8.6 percent of new cancer cases. “(3) Those devastating blood cancers will cause the deaths of an estimated 60,300 persons in the United States in 2001. Every 9 minutes, a person in the United States dies from leukemia, lymphoma, or multiple myeloma. “(4) While less than 5 percent of Federal funds for cancer research are spent on those blood cancers, those blood cancers cause 11 percent of all cancer deaths in the United States. “(5) Increased Federal support of research into leukemia, lymphoma, and multiple myeloma has resulted and will continue to result in significant advances in the treatment, and ultimately the cure, of those blood cancers as well as other cancers.”